Progress in cancer genetics: Lessons from pancreatic cancer
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In the near future advances in the molecular basis of cancer are expected to facilitate cancer diagnosis, to rationalize treatment, to facilitate screening, and to identify individuals requiring cancer prevention strategies. METHODS: The literature was reviewed concerning the genetic alterations that contribute to pancreatic cancer development. RESULTS: Virtually all pancreatic cancers have inactivation of the p16 pathway, and the majority inactivate the TGF beta/DPC4 and p53 tumor-suppressive pathways. Pancreatic cancers with mismatch repair deficiency have a characteristic histology and may have an improved prognosis. The recently discovered tumor suppressor genes, ALK-5, MKK4, and STK11 (the gene responsible for Peutz-Jeghers syndrome) are all targeted for mutation in a small proportion of sporadic pancreatic cancers. Germline mutations of the BRCA2 gene are present in 5-10% of patients with pancreatic cancer. Typically such patients do not have a family history of pancreatic cancer and are mistaken as patients with sporadic disease. Five to 10% of patients with pancreatic cancer have first-degree relatives that will develop pancreatic cancer. Some such families also have a family history of melanoma and harbor germline p16 mutations. However, the gene(s) responsible for much of the inherited predisposition to pancreatic cancer remain to be identified. CONCLUSION: Further advances in pancreatic cancer molecular genetics are needed to facilitate the development of molecular screening tests, to identify additional familial susceptibility genes, and to identify targets for rational therapeutic targeting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 1×
“p53 also contributes to radiation-induced G2 arrest [37,38] which requires the cooperation of the ATM gene product [39].”
BackgroundRole of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
A model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337 · cited 4×
“6. de Winter JP, Roelen BA, ten Dijke P et al. DPC4 (SMAD4) mediates transforming growth factor-beta 1 (TGF-betal) induced growth inhibition and transcriptional response in breast tumour cells.”
BackgroundSelf-citationHypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300 · cited 1×
“Hypoxia induces p53 and this induction can be mediated by HIF-la (hypoxia inducible factor 1 alpha) [32-35], suggesting that the hypoxia present in a cancer nodule selects for cells that have lost p53-mediated hypoxia-induced apoptosis.”
BackgroundZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251
Hereditary Pancreatitis and the Risk of Pancreatic Cancer
Lowenfels, A. B., Maisonneuve, P., DiMagno, E. P., Elitsur, Y., Gates, L. K., Perrault, J., Whitcomb, D. C., & International Hereditary Pancreatitis Study Group (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.6.442 · Cited by 988 · cited 1×
“Carriers have a lifetime risk of pancreas cancer approaching 50% [50,51].”
Background
Cited by
Role of Immune Cells and Immune-Based Therapies in Pancreatitis and Pancreatic Ductal Adenocarcinoma
Zheng, L., Xue, J., Jaffee, E. M., & Habtezion, A. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.12.042 · Cited by 323
Immortal Human Pancreatic Duct Epithelial Cell Lines with Near Normal Genotype and Phenotype
Ouyang, H., Mou, L.-J., Luk, C., Liu, N., Karaskova, J., Squire, J., & Tsao, M.-S. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64800-6 · Cited by 313
(2001) · PubMed · Cited by 309
Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker
Pietrasz, D., Pécuchet, N., Garlan, F., Didelot, A., Dubreuil, O., Doat, S., Imbert-Bismut, F., Karoui, M., Vaillant, J.-C., Taly, V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0806 · Cited by 268
Sato, N., Rosty, C., Jansen, M., Fukushima, N., Ueki, T., Yeo, C. J., Cameron, J. L., Iacobuzio-Donahue, C. A., Hruban, R. H., & Goggins, M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63053-2 · Cited by 267
Self-citation
Metadata
- Authors
- Goggins, M., Kern, S. E., Offerhaus, J. A., & Hruban, R. H.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 1999
- Volume
- 10
- Pages
- S4-S8
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2133076163
- Cited by
- 70
- References
- 11
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progress in cancer genetics: Lessons from pancreatic cancer. https://app.cochat.ai/papers/10.1093/annonc/10.suppl_4.s4
- The paper
- Goggins, M., Kern, S. E., Offerhaus, J. A., & Hruban, R. H. (1999). Progress in cancer genetics: Lessons from pancreatic cancer. Annals of Oncology. https://doi.org/10.1093/annonc/10.suppl_4.s4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.